IP Library Granted Patent US 8,957,104
Granted Patent B2
US 8,957,104 · App. 13/941,911 · Granted Feb 17, 2015

Chemical compounds

Inventors: Philip Stewart Turnbull (Research Triangle Park, NC); Rodolfo Cadilla (Research Triangle Park, NC)
Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
C07D209/08C07D401/06C07D209/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,957,104
App. No.
13/941,911
Granted
Feb 17, 2015
Kind
B2
Abstract

This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.

Claims (12)

1. A compound:

2. A pharmaceutical composition comprising a compound according to claim 1 and one or more pharmaceutically acceptable excipients.

3. A method of treating muscle wasting associated with chronic obstructive pulmonary disease (COPD), wherein said method comprises administering a compound according to claim 1 to a human subject in need thereof.

4. A method of treating muscle wasting associated with chronic kidney disease (CKD), wherein said method comprises administering a compound according to claim 1 to a human subject in need thereof.

5. A method of treating muscle wasting associated with chronic heart failure (CHF), wherein said method comprises administering a compound according to claim 1 to a human subject in need thereof.

6. A method of treating urinary incontinence, wherein said method comprises administering a compound according to claim 1 to a human subject in need thereof.

7. A method of accelerating hip fracture repair and healing, wherein said method comprises administering a compound according to claim 1 to a human subject in need thereof.

8. The method according to claim 3 , wherein 0.1-50 mgs of the compound is administered.

9. The method according to claim 4 , wherein 0.1-50 mgs of the compound is administered.

10. The method according to claim 5 , wherein 0.1-50 mgs of the compound is administered.

11. The method according to claim 6 , wherein 0.1-50 mgs of the compound is administered.

12. The method according to claim 7 , wherein 0.1-50 mgs of the compound is administered.

Assignments (2)
CHANGE OF ADDRESS Recorded Apr 16, 2025
From: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
Reel/Frame 070854/0469 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2014
From: TURNBULL, PHILIP STEWART; CADILLA, RODOLFO
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
Reel/Frame 033628/0405 →
Continuity (3)
Provisional Application 61748874 · Jan 4, 2013
Provisional Application 61672455 · Jul 17, 2012
Related Publication 20140024694A1 · Jan 23, 2014